ArticleFrontiers in oncology2026
Accuracy and clinical utility of the compact micro-robot: a retrospective study of 95 cases.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Robotic platforms for stereotactic neurosurgery have evolved rapidly, but compact systems have not been clinically validated in large cohorts. Objective: To assess targeting accuracy and safety of the compact micro-robot (Q300, 1.5 kg, three-dimensional structured-light registration) across multiple stereotactic procedures, and to contextualize its performance against published data from established platforms. Methods: We retrospectively analyzed 95 consecutive patients who underwent Q300-guided neurosurgery at Beijing Tiantan Hospital (October 2022-August 2024). Procedures included brain biopsy (n=57), ventriculoperitoneal shunt (n=17), CSF bypass procedures (n=17), and catheter drainage (n=4). The primary outcome was targeting error (TE), defined as the Euclidean distance between planned and actual target points on fused postoperative CT. Entry error (EE) was defined as the Euclidean distance between planned and actual entry points on the skull surface. Secondary outcomes included diagnostic yield, complication rate, and operative time. Results: The mean EE was 0.92 ± 0.47 mm (median 0.85, IQR 0.55-1.20), and the mean TE was 0.95 ± 0.56 mm (median 0.88, IQR 0.56-1.22). All 57 biopsies yielded conclusive histopathological diagnosis (100% diagnostic tissue acquisition rate). The complication rate was 6.3% (6/95), including 3 hemorrhages managed conservatively and 3 infections after temporal horn bypass. No mortality or permanent neurological deficit occurred. The mean operative time was 73.8 ± 31.1 min (range 17-240) in 95 procedures. Conclusion: The compact micro-robot achieved submillimetric median accuracy, 100% diagnostic tissue acquisition, and efficient operative times across 95 procedures. Its lightweight design and rapid registration offer practical workflow advantages. The infection rate in temporal horn bypass (3/10) requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.